Want to see SENS full AI Analyst Report?
SENS Stock Chart & Stats
$6.77
-$0.03(-6.68%)
At close: 4:00 PM EST
$6.77
-$0.03(-6.68%)
Day’s Range― - ―
52-Week Range$4.79 - $12.56
Previous CloseN/A
Volume3.00M
Average Volume (3M)767.85K
Market Cap
$277.20M
Enterprise Value$292.82M
Total Cash (Recent Filing)$64.64M
Total Debt (Recent Filing)$43.14M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Aug 06, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.16
Shares Outstanding52,202,965
10 Day Avg. Volume1,159,308
30 Day Avg. Volume767,845
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.77
Price to Sales (P/S)6.53
P/FCF Ratio-3.82
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue7.19
Enterprise Value/Gross Profit13.81
Enterprise Value/Ebitda-3.62
Forecast
1Y Price Target
$17.00Price Target Upside151.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.4
Revenue Forecast (FY)$62.30M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Raised GuidanceConsistent high top-line growth and an upgraded full-year guide indicate durable demand and improving commercial execution. Q1 revenue up 85% and guidance to $60–$64M imply expanding patient adoption, higher reorder cadence and scaleable revenue streams over the next 2–6 months.
Sustained Gross Margin ExpansionMaterial gross margin expansion to ~58% in Q1 and guidance of 55–58% points to favorable unit economics for the implantable CGM. The product’s long-duration sensor and recurring consumable/replacement model support durable margin sustainability as volumes rise and fixed costs are absorbed.
Consolidation Of European OperationsAcquiring Ascensia's local European assets is a structural shift to direct control of EU commercialization. This consolidation reduces partner dependency, improves go-to-market consistency, enables unified contracting and pricing, and should strengthen long-term operational execution and margin capture in key EU markets.
Bears Say
Persistent Cash BurnLarge negative operating cash flow and FCF reveal continued reliance on external capital to fund commercialization. With projected 2026 cash utilization of $110–$120M, the company faces ongoing dilution and refinancing risk if revenue growth or conversion efficiency decelerates, constraining strategic optionality.
Elevated Leverage And Weakened EquityLeverage has meaningfully increased, reducing financial flexibility. A higher debt-to-equity ratio amid negative earnings raises refinancing and covenant risk and increases interest burden exposure, limiting the company’s ability to absorb setbacks during an intensive commercialization and clinical-investment period.
High Operating Expenses And Widening LossesIn-house commercial integration and DTC scale-up have sharply increased SG&A and R&D, widening net losses. Management budgets $150–160M in operating expenses for 2026, so profitability hinges on sustaining DTC efficiency, HCP adoption and retention; failure to do so will magnify funding needs and execution risk.
Senseonics Holdings News
SENS FAQ
What was Senseonics Holdings Inc.’s price range in the past 12 months?
Senseonics Holdings Inc. lowest stock price was $4.79 and its highest was $12.56 in the past 12 months.
What is Senseonics Holdings Inc.’s market cap?
Senseonics Holdings Inc.’s market cap is $277.20M.
When is Senseonics Holdings Inc.’s upcoming earnings report date?
Senseonics Holdings Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 28 days.
How were Senseonics Holdings Inc.’s earnings last quarter?
Senseonics Holdings Inc. released its earnings results on May 07, 2026. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.686 by -$0.024.
Is Senseonics Holdings Inc. overvalued?
According to Wall Street analysts Senseonics Holdings Inc.’s price is currently Undervalued.
Does Senseonics Holdings Inc. pay dividends?
Senseonics Holdings Inc. does not currently pay dividends.
What is Senseonics Holdings Inc.’s EPS estimate?
Senseonics Holdings Inc.’s EPS estimate is -0.61.
How many shares outstanding does Senseonics Holdings Inc. have?
Senseonics Holdings Inc. has 52,202,965 shares outstanding.
What happened to Senseonics Holdings Inc.’s price movement after its last earnings report?
Senseonics Holdings Inc. reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.686. Following the earnings report the stock price went down -6.157%.
Which hedge fund is a major shareholder of Senseonics Holdings Inc.?
Currently, no hedge funds are holding shares in SENS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Senseonics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.00 (151.11% Upside)
$17.00 (151.11% Upside)
Blogger Sentiment
Bullish
SENS Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $126.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.38%
12-Months-Change
Fundamentals
Return on Equity
-130.00%
Trailing 12-Months
Asset Growth
17.94%
Trailing 12-Months
Company Description
Senseonics Holdings Inc.
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
SENS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial momentum and validating financial results: Q1 revenue of $11.7M (up 85% YoY), a 58% gross margin, rapid DTC growth (~100% YoY) and successful U.S. commercial integration. Management raised 2026 revenue guidance to $60M–$64M (70%–82% growth) and advanced pipeline milestones (Gemini and Freedom) while adding substantial growth capital ($92M equity + expanded $140M credit facility with a $20M draw). Offsetting these positives are materially higher operating expenses and an expanded net loss driven by in‑house commercialization, significant planned cash burn ($110M–$120M for 2026), increased debt, and remaining execution risk in the European transition and competitive landscape. On balance, the highlights from stronger-than-expected top-line performance, margin expansion and financing to fund growth outweigh the near-term cost and cash challenges, but execution through the rest of 2026 will be key.View all SENS earnings summariesSENS Stock 12 Month Forecast
Average Price Target
$17.00
▲(151.11% Upside)
Technical Analysis
Ownership Overview
5.78% Insiders
4.26% Mutual Funds
5.46% Other Institutional Investors
77.29% Public Companies and
Individual Investors